Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment. He suggests that more careful healthcare spending could support the high costs, and deliver the potential benefits of these drug combinations. "This situation is not unique to breast cancer," said Kolodziej. "You can extrapolate it to just about any disease we treat these days.
This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
September 17th 2025
- Radiotherapy Raises Risk of Complications After Limb STS Surgery
September 16th 2025
- miRNA Profiling May Unlock SCLC Biomarkers
September 13th 2025